Pathology News
editor

About Editor

This author has not yet filled in any details.
So far Editor has created 933 blog entries.

July 2025

Paige Releases PRISM2: A Whole-Slide Foundation Model for Multimodal AI in Pathology and Cancer Care

2025-07-28T10:34:46+00:00

Built on over 2.3 million whole-slide images and integrated with Microsoft’s Phi-3, PRISM2 sets a new benchmark in performance, interpretability, and large language model compatibility Paige, a leader in next-generation AI technology, today announced the release of PRISM2, its most advanced slide-level foundation model to date. PRISM2 is designed to advance large language models (LLM) by [...]

Paige Releases PRISM2: A Whole-Slide Foundation Model for Multimodal AI in Pathology and Cancer Care2025-07-28T10:34:46+00:00

Rewiring the Laboratory’s Bottom Line: Moving Towards Digital Pathology as a Profit Center

2025-07-25T07:22:33+00:00

By Tom Gallo & Arun Ananth Tom Gallo is Proscia’s Chief Financial Officer. Arun Ananth is the company’s Chief Commercial Officer.  For years, AI-driven pathology has promised to deliver top- and bottom-line impact for diagnostic laboratories, but its initial economic value has come from gains in efficiency and throughput. These benefits deliver early wins, helping [...]

Rewiring the Laboratory’s Bottom Line: Moving Towards Digital Pathology as a Profit Center2025-07-25T07:22:33+00:00

Prediction of Patient Prognosis from Digitized Pathology Slides in Early Breast Cancer (ER+/HER2-)

2025-07-24T09:22:12+00:00

Context Breast cancer (BC) remains the leading cause of cancer death for women worldwide, despite therapeutic advances. Understanding a patient's likelihood of reoccurrence is critical to determine their treatment strategy. However, assessing this risk is not always straightforward due to the heterogeneity of disease and range of subtypes associated to disease prognosis. Methods Owkin developed [...]

Prediction of Patient Prognosis from Digitized Pathology Slides in Early Breast Cancer (ER+/HER2-)2025-07-24T09:22:12+00:00

Collaboration Between UT and UTMC Could Revolutionize Breast Cancer Diagnosis

2025-07-24T08:52:20+00:00

Researchers in the University of Tennessee, Knoxville’s Tickle College of Engineering are using artificial intelligence and machine learning to provide treatment plans to breast cancer patients more quickly by analyzing pathology reports and other clinical records to determine how much breast cancer is in the body. Breast cancer is the second most common cancer in Tennessee and the [...]

Collaboration Between UT and UTMC Could Revolutionize Breast Cancer Diagnosis2025-07-24T08:52:20+00:00

Genomics and Digital Pathology: Driving the NHS 10-Year Plan for Proactive Health

2025-07-23T07:52:31+00:00

Author: Sidney Ocanagil-Tunstall Photography: Leo Hillier and Shanice Montgomery On 10th July, Pathology News visited Source Genomics’ headquarters in Cambridge to witness the launch of Source BioScience’s new partnership with Cambridge Clinical Laboratories (CCL). Acquired in April 2025, CCL serves both the NHS and private sectors, offering personalised diagnostic services across oncology, virology, gastroenterology, men’s [...]

Genomics and Digital Pathology: Driving the NHS 10-Year Plan for Proactive Health2025-07-23T07:52:31+00:00

Study Shows How AI Could Help Pathologists Match Cancer Patients to the Right Treatments – Faster and More Efficiently

2025-07-22T14:35:19+00:00

A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and collaborators, suggests that artificial intelligence (AI) could significantly improve how doctors determine the best treatment for cancer patients—by enhancing how tumor samples are analyzed in the lab. The findings, published in the July 9 online [...]

Study Shows How AI Could Help Pathologists Match Cancer Patients to the Right Treatments – Faster and More Efficiently2025-07-22T14:35:19+00:00

Proscia Cements Leadership in Diagnostic Pathology with 400% Growth in Daily Cases

2025-07-21T15:40:05+00:00

Amid momentum, the company generates millions in new high-margin revenue for diagnostic network Introduces AI application suites to demonstrate the future of pathology for high-impact use cases Launches 24/7 support to meet the demands of mission-critical, high-throughput operations across expanding global customer base Completes integrations with 100+ LIS instances, including Epic Beaker, reflecting Concentriq’s role in [...]

Proscia Cements Leadership in Diagnostic Pathology with 400% Growth in Daily Cases2025-07-21T15:40:05+00:00

Can an AI Diagnostic Help Doctors Make More Precise Treatment Decisions for Breast Cancer?

2025-07-18T15:08:42+00:00

In a recent Nature Communications article1 a preliminary version of Owkin’s RlapsRisk® BC uses AI to bring a new layer of insight to breast cancer diagnosis, helping reveal which patients may be at risk of relapse. The clinical dilemma Despite significant progress in diagnosis and treatment, breast cancer (BC) continues to be  the leading cause of death [...]

Can an AI Diagnostic Help Doctors Make More Precise Treatment Decisions for Breast Cancer?2025-07-18T15:08:42+00:00

Celebrating the Launch of Source Genomics X Cambridge Clinical Laboratories

2025-10-02T13:35:16+00:00

On Thursday 10th July, Source Genomics officially marked the acquisition of Cambridge Clinical Laboratories with a launch event at its Cambridge headquarters, Endeavour House. The event welcomed a wide range of attendees, including industry colleagues, collaborators, and partners, to explore how genomics is playing an increasingly central role in the future of clinical diagnostics. The afternoon [...]

Celebrating the Launch of Source Genomics X Cambridge Clinical Laboratories2025-10-02T13:35:16+00:00

Discussion with the Expert: Q&A with Founder/CEO Andrew Beck, M.D., Ph.D., on AISight® Dx FDA Clearance and the Future of Digital Pathology

2025-07-18T09:02:09+00:00

Recently PathAI announced exciting news: AISight® Dx has received FDA clearance for primary diagnosis in clinical settings! Check out our full press release for more details on the news. Following AISight Dx’s FDA milestone, we sat down with PathAI Co-Founder and CEO Andy Beck to explore what the clearance means for our customers and the future [...]

Discussion with the Expert: Q&A with Founder/CEO Andrew Beck, M.D., Ph.D., on AISight® Dx FDA Clearance and the Future of Digital Pathology2025-07-18T09:02:09+00:00
Legal

Bioincyte Ltd is registered in the United Kingdom
under company number 13037659

Get in touch

© Copyright 2025, Bioincyte Ltd

Fields marked with an asterisk (*) are required.
By submitting you agree to our T&C and Privacy Policy

Go to Top